European Institute of Oncology

ieo.it

Total trials

171

Active

75

Phase 3

15

Total enrollment

83,442

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 12 of 12 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
BRCA testing1
Prasterone1
Chemotherapy2
Pembrolizumab2
Tamoxifen 10 mg1
elacestrant and exemestane1
Temozolomide1
Atezolizumab in combination with Cyclophosphamide and Vinorelbine1
Sophia DDM1
Neoadjuvant standard treatment for HER2+1
Adjuvant standard treatment for HER2+1
ctDNA detection1

Next readouts

  • 2024-12-01
  • 2024-12-31
  • 2025-03
  • 2025-12
  • 2025-12-30
  • 2026-12-15
  • 2027-01-01
  • 2027-04
  • 2027-11
  • 2028-12

Top conditions

  • Breast Cancer39
  • Lung Cancer6
  • Colorectal Cancer6
  • Head and Neck Cancer6
  • Metastatic Breast Cancer5
  • Prostate Cancer5
  • Neuroendocrine Tumors4
  • Neuroendocrine Neoplasm4

Frequently asked questions about European Institute of Oncology

How many clinical trials does European Institute of Oncology have on ClinicalTrials.gov?
European Institute of Oncology is listed as the lead sponsor on 171 clinical trials in ClinicalTrials.gov, 75 of which are currently active (recruiting, enrolling, or ongoing).
How many of European Institute of Oncology's trials are in Phase 3?
15 of European Institute of Oncology's trials are in Phase 3, spread across 12 active drug programs.
What therapeutic areas does European Institute of Oncology focus on?
European Institute of Oncology's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Lung Cancer, Colorectal Cancer, Head and Neck Cancer, Metastatic Breast Cancer.
When are European Institute of Oncology's next clinical trial readouts?
European Institute of Oncology has 10 upcoming primary-completion readouts tracked here; the soonest is “Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer”, expected around 2024-12-01.